Hong Kong, China

Edward Wong

Hong Kong Center for Clinical Research

Osteoarthritis

Knee Osteoarthritis

Hyperuricemia

Joint Diseases

Musculoskeletal Diseases

Gout

Arthritis

Pain

Gouty Arthritis

Asthma

AMZ001

JTA-004

Rocatinlimab

Baxdrostat

AR882

KBP-336

LEVI-04

Amgen

Amzell

Arthrosi Therapeutics

AstraZeneca

Bone Therapeutics

Danone

KeyBioscience

Levicept

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The goal of this clinical trial is to learn if KBP-336 works to treat pain in osteoarthritis in individuals living with obesity. It will also learn about the effects on other parameters, such as quality of life and metabolism, as well as safety of KBP-336. The main questions it aims to answer are:

* Does KBP-336 lower knee pain from osteoarthritis in individuals with obesity
* Does KBP-336 lower bodyweight in the same population. Researchers will compare KBP-336 to a placebo (a look-alike substance that contains no drug) to see if KBP-336 works to pain and obesity

Participants will:

* Take KBP-336 or a placebo every week for 6 months
* Visit the clinic once every 2 weeks for checkups and tests
* Keep a diary of their symptoms and the amount of medication they use in addition to KBP-336

Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis

Hong Kong Center for Clinical Research | Hong Kong, China

Site insights

Contact this site

Active trials

Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis

Trial sponsors